Pazopanib is an oral multitarget tyrosine kinase inhibitor (TKI) with a clinical antitumor effect that is thought to be exerted through its selective inhibition of vascular endothelial growth factor receptor (VEGFR)-mediated angiogenesis, as well as its direct blockade of growth-promoting receptor tyrosine kinases (RTKs).
It is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma, and which demonstrated promising overall survival of patients in SS related studies.
Previously conducted studies demonstrated that SS has multiple therapeutic targets, such as vascular endothelial growth factor, and new emerging targets. This indicates that different systemic therapeutic interventions should be considered for the development of new treatment options other than just chemotherapy.
In addition, a better understanding of the molecular and immunologic characteristics of SS has allowed for the identification of new potential targets and the development of novel biology-driven therapies that are all at different stages of testing. These include targeted agents, immunotherapy, and metabolic therapies.
Because the impact of these strategies for improving SS outcome is still limited, current and future research are strongly needed to understand the tumor biology better, to identify predictive biomarkers, and to improve the outcomes for patients with SS. Given their diversity, heterogeneity, complexity, and rarity, the clinical management of sarcomas is quite challenging.
Despite these limitations and challenges the market growth during the forecast period (2019–2028) is expected to be positive.
Read More @ Synovial Sarcoma Market Research Report
Comments